PLBIO(SZ:000403) Zhong Guo Jing Ji Wang·2025-06-10 07:43Core Viewpoint - The company, Palin Bio (000403.SZ), has resumed trading after announcing a significant change in control, with its major shareholder, Shengbang Yinghao, planning to transfer 21.03% of its shares to China National Pharmaceutical Group (China Bio) [1][2]. Group 1: Stock Performance - Upon resuming trading, the stock opened at a limit-up price of 18.66 yuan, reflecting a 10.02% increase, but closed at 17.14 yuan, with a final gain of 1.06% [1]. Group 2: Control Change Announcement - The transfer of shares will result in a change of the controlling shareholder from Shengbang Yinghao to China Bio, and the actual controller will shift from the Shaanxi Provincial Government's State-owned Assets Supervision and Administration Commission to China National Pharmaceutical Group [1][2]. - The company has stated that this change in control will not adversely affect its normal operations and will not harm the interests of the company or minority shareholders [2]. Group 3: Due Diligence and Regulatory Requirements - Following the signing of the acquisition framework agreement, China Bio will conduct due diligence, and the completion of this process is necessary before any further agreements can be signed [2]. - The transaction is subject to compliance confirmation from the Shenzhen Stock Exchange and must undergo share transfer registration with the China Securities Depository and Clearing Corporation [2].